CD8 T Cell Therapy Response Prediction Using CXCR3 Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapies, such as immune-checkpoint blockade, have limited response rates, particularly in less immunogenic tumor types, and there is a need to improve treatment strategies and predict patient responses effectively.
Innovation Solution
Assessing CXCR3-positive T cell levels in peripheral blood and tumor samples following CD8 T cell-mediated immune therapy to predict treatment response, and using inhibitors like TGFβR1 inhibitors or immune checkpoint blockers, with additional therapies like chemotherapy and radiation, to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune-checkpoint blockade is used for cancer treatment, then immune response is enhanced, but response rate remains limited particularly in less immunogenic tumor types
Solution Approach 1:
The patent combines immune-checkpoint blockade with TGFβR1 inhibition in a dual-therapy approach. This merging of two distinct immunotherapeutic mechanisms addresses the limitation of single-agent therapy by simultaneously enhancing immune activation while removing suppressive signals, thereby improving response rates across diverse tumor types including less immunogenic cancers.
Solution Approach 2:
The treatment regimen functions as a composite immunotherapeutic strategy, integrating multiple therapeutic agents (immune checkpoint inhibitors and TGFβR1 inhibitors) that work through different mechanisms. This composite approach creates synergistic effects that overcome the limitations of individual therapies and expand adaptability to various cancer types.
2Reliability
If combination therapy with chemo- and/or radiation therapy is implemented, then treatment efficacy may be improved, but successful combination has been slower to gain clinical traction
Solution Approach 1:
The patent employs TGFβR1 inhibition as a preliminary action before or concurrent with immune-checkpoint blockade and chemoradiation. By pre-conditioning the tumor microenvironment to reduce immunosuppression and enhance immune cell infiltration, the subsequent immune therapy and chemotherapy/radiation become more effective, thereby simplifying the overall treatment approach while maintaining high efficacy.
Solution Approach 2:
TGFβR1 inhibition acts as an intermediary mechanism that mediates between the tumor microenvironment and the immune system. By blocking TGFβ signaling, it creates a permissive environment that facilitates the action of immune checkpoint inhibitors and chemoradiation, effectively bridging these therapeutic modalities and improving their combined efficacy.
3Measurement precision
If CXCR3-positive T cell levels are monitored to predict treatment response, then treatment selection can be optimized, but additional testing time and complexity are required
Solution Approach 1:
The patent utilizes baseline CXCR3-positive T cell measurement as a preliminary predictive marker before initiating therapy. This allows for pre-screening and selection of patients most likely to respond to the combination immunotherapy regimen, thereby avoiding unnecessary treatment delays and focusing resources on responsive patients while maintaining high prediction accuracy.
Data Source
AI summary
Methods of treating a subject with cancer with CD8 T cell-mediated immune therapy are provided. The methods include measuring an amount of CXCR3-positive T cells in a peripheral blood sample or a tumor sample from a subject with cancer following treatment of the subject with at least one dose of the CD8 T cell-mediated therapy and comparing the amount of CXCR3-positive T cells in the sample to a control. Responsiveness of the cancer to the CD8 T cell-mediated therapy is predicted based on whether there is an increase or decrease in the amount of CXCR3-positive T cells in the sample. Methods further including treating the subject with at least one additional dose of the CD8 T cell-mediated immune therapy are also provided.